Zai Lab Limited (HKG:9688)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 23.68B +10.4% |
| Revenue (ttm) | 3.47B +0.0% |
| Net Income | -1.56B |
| EPS | -1.40 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,040,000 |
| Open | 21.06 |
| Previous Close | 20.96 |
| Day's Range | 20.90 - 21.50 |
| 52-Week Range | 12.31 - 21.50 |
| Beta | 0.72 |
| Analysts | Buy |
| Price Target | 21.03 (-2.09%) |
| Earnings Date | Nov 5, 2026 |
About Zai Lab
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter... [Read more]
Financial Performance
In 2025, Zai Lab's revenue was $460.16 million, an increase of 15.33% compared to the previous year's $398.99 million. Losses were -$175.54 million, -31.73% less than in 2024.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for 9688 stock is "Buy." The 12-month stock price target is $21.03, which is a decrease of -2.09% from the latest price.
News
Consensus Price Target for Zai Lab Limited - Depositary Receipt Increased by 12.10% to $31.30
The average one-year price target for Zai Lab Limited - Depositary Receipt (NASDAQGM:ZLAB) (DB:1ZL) has been revised to $31.30 / share, as of November 8, 2026. This represents an increase of 12.10% fr...
Zai Lab Q3 Earnings Call Highlights
Zai Lab NASDAQ: ZLAB reported $108.2 million in third-quarter revenue and said it expects to return to year-over-year product revenue growth in 2027, while advancing its lead cancer drug candidate tow...
Zai Lab (ZLAB) Q3 2026 Earnings Call Transcript
Zai Lab's China business stabilizes as its lead cancer drug nears a 2027 filing.
Zai Lab presents updated clinical data on zocilurtatug pelitecan
Zai Lab (ZLAB) announced that updated data from a Phase 1b/2 trial of zocilurtatug pelitecan, a DLL3-targeting antibody-drug conjugate, will be shared tomorrow at the North American Neuroendocrine Tum...
Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that updated data from a Phase 1b/2 trial of z...
Zai Lab Earnings Call Transcript: Q3 2026
Q3 revenue was $108.2M, China product revenue rose 2% sequentially, and the commercial business remained profitable. Zoci’s early SCLC data supported an advancing global phase III program, with a potential U.S. filing in 2027.
Zai Lab Earnings release: Q3 2026
Zai Lab released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Zai Lab Quarterly report: Q3 2026
Zai Lab has published its Q3 2026 quarterly earnings report on November 5, 2026.
Zai Lab Slides: Q3 2026
Zai Lab has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Zai Lab Releases Q3 2026 Financial Results
Zai Lab Limited posted a narrower-than-expected third quarter loss, as the China-focused biopharmaceutical company continues navigating a challenging commercial environment for its oncology and immuno...
Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma, today announced financial results for the third quarter of 2026, along...
Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study
Zai Lab NASDAQ: ZLAB presented early-stage data at the 2026 European Society for Medical Oncology meeting for zoci, its DLL3-targeted antibody-drug conjugate, in combination with atezolizumab, with or...
Zai Lab Transcript: Investor update
Zoci plus atezolizumab showed an 81.8% confirmed ORR and 81.9% 6-month PFS at 1.6 mg/kg in first-line SCLC, with encouraging tolerability. A frontline Phase III doublet study is targeted to start by year-end 2026.
Zai Lab Press release: Investor update
Zai Lab issued a press release on October 23, 2026, disclosing material business information to investors.
Zai Lab Slides: Investor update
Zai Lab has posted slides in relation to its latest quarterly earnings report, which was published on October 23, 2026.
Zai Lab Limited Announces $250 Million Private Placement
Zai Lab Limited entered into a securities purchase agreement on October 22, 2026, with certain accredited investors to sell 11,340,000 American depositary shares (ADSs) in a private placement transact...
Zai Lab reports results from Phase 1b trial of zocilurtatug pelitecan
Zai Lab (ZLAB) shared the first data from a global Phase 1b clinical trial evaluating zocilurtatug pelitecan in combination with atezolizumab with and without carboplatin as first-line treatment for e...
Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today shared the first data from a global Phase 1b clinical tr...
Zai Lab announces $250M private placement
Zai Lab (ZLAB) Limited announced that it has entered into a securities purchase agreement for the sale of 11,340,000 American Depositary Shares, each representing ten ordinary shares of the Company,…
Zai Lab Announces $250 Million Private Placement
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) an innovation-driven, global biopharma company, today announced that it has entered into a securities purchase ...
Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its third quarter 2026 financial results and provide recent corporate updat...
Zai Lab management to meet with Cantor
Group Dinner Meeting with Management to be held in Madrid on October 23 hosted by Cantor.
Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from the first clinical trial evaluating ZL-1503, the company's internally developed ...
Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-131...
Zai Lab price target raised to $36 from $27 at JPMorgan
JPMorgan raised the firm’s price target on Zai Lab (ZLAB) to $36 from $27 and keeps an Overweight rating on the shares. The firm updated the company’s model. Published first…